Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 1:348:g1903.
doi: 10.1136/bmj.g1903.

Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies

Rajiv Chowdhury  1 , Setor Kunutsor, Anna Vitezova, Clare Oliver-Williams, Susmita Chowdhury, Jessica C Kiefte-de-Jong, Hassan Khan, Cristina P Baena, Dorairaj Prabhakaran, Moshe B Hoshen, Becca S Feldman, An Pan, Laura Johnson, Francesca Crowe, Frank B Hu, Oscar H Franco
Affiliations
Review

Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies

Rajiv Chowdhury et al. BMJ. .

Abstract

Objective: To evaluate the extent to which circulating biomarker and supplements of vitamin D are associated with mortality from cardiovascular, cancer, or other conditions, under various circumstances.

Design: Systematic review and meta-analysis of observational studies and randomised controlled trials.

Data sources: Medline, Embase, Cochrane Library, and reference lists of relevant studies to August 2013; correspondance with investigators.

Study selection: Observational cohort studies and randomised controlled trials in adults, which reported associations between vitamin D (measured as circulating 25-hydroxyvitamin D concentration or vitamin D supplement given singly) and cause specific mortality outcomes.

Data extraction: Data were extracted by two independent investigators, and a consensus was reached with involvement of a third. Study specific relative risks from 73 cohort studies (849,412 participants) and 22 randomised controlled trials (vitamin D given alone versus placebo or no treatment; 30,716 participants) were meta-analysed using random effects models and were grouped by study and population characteristics.

Results: In the primary prevention observational studies, comparing bottom versus top thirds of baseline circulating 25-hydroxyvitamin D distribution, pooled relative risks were 1.35 (95% confidence interval 1.13 to 1.61) for death from cardiovascular disease, 1.14 (1.01 to 1.29) for death from cancer, 1.30 (1.07 to 1.59) for non-vascular, non-cancer death, and 1.35 (1.22 to 1.49) for all cause mortality. Subgroup analyses in the observational studies indicated that risk of mortality was significantly higher in studies with lower baseline use of vitamin D supplements. In randomised controlled trials, relative risks for all cause mortality were 0.89 (0.80 to 0.99) for vitamin D3 supplementation and 1.04 (0.97 to 1.11) for vitamin D2 supplementation. The effects observed for vitamin D3 supplementation remained unchanged when grouped by various characteristics. However, for vitamin D2 supplementation, increased risks of mortality were observed in studies with lower intervention doses and shorter average intervention periods.

Conclusions: Evidence from observational studies indicates inverse associations of circulating 25-hydroxyvitamin D with risks of death due to cardiovascular disease, cancer, and other causes. Supplementation with vitamin D3 significantly reduces overall mortality among older adults; however, before any widespread supplementation, further investigations will be required to establish the optimal dose and duration and whether vitamin D3 and D2 have different effects on mortality risk.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding authors) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Association of circulating 25-hydroxyvitamin D concentrations with cause specific mortality in observational cohort studies. *Pooled estimates are based on random effects meta-analysis. Using fixed effects models, for primary prevention cohorts, secondary prevention cohorts, and all cohorts, the estimates were 1.40 (1.32 to 1.47), 1.50 (1.35 to 1.66), and 1.42 (1.35 to 1.49) for cardiovascular deaths; 1.10 (1.02 to 1.17), 1.45 (1.28 to 1.65), and 1.16 (1.10 to 1.24) for cancer deaths; 1.28 (1.12 to 1.47), 1.38 (1.09 to 1.75), and 1.30 (1.16 to 1.47) for non-vascular, non-cancer deaths; and 1.45 (1.41 to 1.49), 1.49 (1.42 to 1.56), and 1.44 (1.40 to 1.47) for all cause deaths. Size of data marker is proportional to inverse of variance of relative risk; horizontal line represents 95% CI. Corresponding forest plots and I2 (95% CI) estimates are provided in supplementary material
None
Fig 2 Association of circulating 25-hydroxyvitamin D concentrations with all cause mortality, based on primary prevention cohorts. *Indirect comparisons based on available studies with relevant information in each category; summary estimates presented were calculated using random effects models. Using fixed effects models, the estimates were 1.09 (1.06 to 1.11) for clinical cut-off of 21-29 v ≥30, 1.20 (1.15 to 1.26) for 10-20 v ≥30, 1.23 (1.20 to 1.26) for <10 v ≥30, and 1.19 (1.18 to 1.21) per 10 ng/mL decrease
None
Fig 3 Association of circulating 25-hydroxyvitamin D concentration and risk of cardiovascular disease mortality in primary prevention cohorts, according to various characteristics. Based on available studies with relevant subgroup information. CPBA=competitive binding protein assay; +=relative risks adjusted for established cardiovascular risk factors such as age, sex, smoking status, lipids, hypertension, history of cardiometabolic disease; ++=adjusted for other potential risk factors such as physical activity, body mass index, social status; +++=adjusted for other additional variables such as bone minerals. *P<0.05 from meta-regression analyses. †Based on available studies with relevant subgroup information. ‡Based on Newcastle-Ottawa scale.
None
Fig 4 Association of circulating 25-hydroxyvitamin D concentration and risk of cancer mortality in primary prevention cohorts, according to various characteristics. Based on available studies with relevant subgroup information. CPBA=competitive binding protein assay; +=relative risks adjusted for established cardiovascular risk factors such as age, sex, smoking status, lipids, hypertension, history of cardiometabolic disease; ++=adjusted for other potential risk factors such as physical activity, body mass index, social status; +++=adjusted for other additional variables such as bone minerals. *P<0.05 from meta-regression analyses. †Based on available studies with relevant subgroup information. ‡Based on Newcastle-Ottawa scale.
None
Fig 5 Association of circulating 25-hydroxyvitamin D concentration and risk of all cause mortality in primary prevention cohorts, according to various characteristics. Based on available studies with relevant subgroup information. CPBA=competitive binding protein assay; +=relative risks adjusted for established cardiovascular risk factors such as age, sex, smoking status, lipids, hypertension, history of cardiometabolic disease; ++=adjusted for other potential risk factors such as physical activity, body mass index, social status; +++=adjusted for other additional variables such as bone minerals. *P<0.05 from meta-regression analyses. †Based on available studies with relevant subgroup information. ‡Based on Newcastle-Ottawa scale.
None
Fig 6 Effects of vitamin D supplementation on all cause mortality when given alone, derived from available randomised control trials. *Pooled estimates are based on random effects meta-analysis. Using fixed effects models, for community dwelling, hospital based, and overall population, the estimates were 0.91 (0.81 to 1.01), 0.88 (0.77 to 1.01), and 0.90 (0.82 to 0.98) for vitamin D3 trials and 1.05 (0.94 to 1.17), 1.15 (0.63 to 2.11), and 1.03 (0.97 to 1.09) for vitamin D2 trials. Overall fixed effect estimate for all trials was 0.98 (0.94 to 1.03). Size of data marker is proportional to inverse of variance of relative risk; horizontal line represents 95% CI. Corresponding forest plots and I2 (95% CI) estimates are provided in supplementary material
None
Fig 7 Effects of vitamin D supplementation on all cause mortality, derived from available randomised controlled trials and according to various characteristics. Based on available studies with relevant subgroup information; P values are from meta-regression analyses. *Low risk and high risk categories are defined by studies that met ≥5 criteria versus those that met <5 criteria in Cochrane Collaboration’s tool, respectively
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Holick MF. Vitamin D: physiology, dietary sources and requirements. In: Encyclopedia of human nutrition. 2nd ed. Academic Press, 2005.
    1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. - PubMed
    1. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012;367:40-9. - PubMed
    1. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006. - PubMed
    1. Winzenberg TM, Powell S, Shaw KA, Jones G. Vitamin D supplementation for improving bone mineral density in children. Cochrane Database Syst Rev 2010;(10):CD006944. - PubMed